NeuroPace

82% Median Seizure Reduction at 3 Years. Life changing outcomes, Confident Care. The RNS® System Post-Approval Study, now published in Neurology, reveals sustained long-term outcomes for drug-resistant focal epilepsy. Discover how this data is setting a new benchmark. See the full study results: https://bit.ly/3QoLTr0 --- RNS System Safety Info: www.neuropace.com/safety

RNS® Therapy made its primetime debut and your patients may have seen it. In the Season 2 finale of The Pitt, a physician character living with Focal Impaired Awareness Seizures (FIAS) is described as relying on a "neuromodulation device which can sense and stop the seizures almost immediately." That's a real description of how the NeuroPace RNS System works; detecting and responding to abnormal electrical activity in real time. For neurologists and epileptologists, this is a meaningful cultural moment. When drug-resistant epilepsy and neuromodulation reach a mainstream audience, patients come to their next appointment with new awareness and new questions. If your patients are asking about closed-loop neuromodulation after watching The Pitt, we'd welcome the conversation. 🔗 https://lnkd.in/g-Q9HyzQ #RNSTherapy #NeuroPace #DrugResistantEpilepsy #Epilepsy #Neuromodulation #Neurology #Epileptology RNS System Safety Info: www.neuropace.com/safety

NeuroPace started 2026 with a strong first quarter. During our earnings call today we reported $22.1 M in revenue, with core RNS System revenue up ~20% year over year. We also raised full year revenue guidance to $99-$101M (21-23% growth) with gross margins expected to be 81.5% - 82.5% and strong operating expense leverage. We remain focused on three key priorities as we move through 2026: → Market development: commercial execution and expanding access to brain-responsive neuromodulation → Clinical development: advancing indication expansion to Drug Resistant Idiopathic Generalized Epilepsy patients → Product development: continuing to advance our AI efforts aimed at making RNS data management more efficient and scalable Our full earnings release and webcast replay available on our investor relations site https://lnkd.in/gcES8_Mk #NPCE #NeuroPace #Earnings #MedTech #Epilepsy #Neuromodulation

To the moms living with epilepsy—and the moms who care for someone who does— Your strength inspires us. 💐 Happy Mother’s Day. #MothersDay #EpilepsyMoms

Heading to ASSFN? Join NeuroPace for our exclusive Breakfast Symposium on Monday, June 1. Explore the evolving role of responsive thalamic neuromodulation for drug-resistant epilepsy. Hear the latest on:
 - Patient Selection & Thalamic Targeting for Focal Epilepsy
 -18-Month Results from the NAUTILUS Study for drug-resistant IGE
 - Feasibility Study of Responsive Stimulation for Lennox-Gastaut Syndrome
 Space is limited to 100 seats for this event. Secure your spot today: https://lnkd.in/gbrrVppW CAUTION - Investigational device. Limited by United States law to investigational use for Idiopathic Generalized Epilepsy (IGE) and Lennox-Gastaut Syndrome (LGS). Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at https://lnkd.in/gXAA3HV

Are you a fellow attending ASSFN this year? Transitioning from fellowship to practice comes with unique challenges and opportunities.

 Join the NeuroPace team and your colleagues for an exclusive Fellows Dinner on Saturday, May 30, at 6:00 PM. We will be discussing strategies for building a successful neuromodulation practice post-fellowship, including:
 • Starting and building your practice as you transition to your first attending role
 • Optimizing clinical efficiency in the neuromodulation clinic
 • Network with thought leaders and colleagues
 • Ask questions that will help you succeed after fellowship
 
 This event is limited to just 30 seats. Reserve yours here: https://lnkd.in/gXNkVTh6

#NursesWeek To every nurse supporting people with epilepsy—you make a difference every day. Thank you for the compassion, care, and commitment. 🩺💜 #ThankYouNurses #EpilepsyCare

Life changing outcomes, Confident Care. Long-term efficacy is a critical goal in treating drug-resistant epilepsy. The newly published 3-year results from the RNS® System Post-Approval Study in Neurology provide a comprehensive look at sustained outcomes. Review the full study here: https://bit.ly/3QoLTr0 --- RNS System Safety Info: www.neuropace.com/safety

Life changing outcomes, Confident Care. The 3-year RNS® System Post-Approval Study results are now available in Neurology. See the results that are informing the new standard of care. Read the full publication now:€https://bit.ly/3QoLTr0 --- RNS System Safety Info: www.neuropace.com/safety

When a primetime TV drama features your technology, you take notice. In the Season 2 finale of The Pitt, "9:00 P.M.," Dr. Baran Al-Hashimi reveals she's been living with Focal Impaired Awareness Seizures (FIAS) — the cause of the mysterious "freezing" episodes seen all season. In the episode, her care team references a "neuromodulation device which can sense and stop the seizures almost immediately." That's RNS® Therapy. That's NeuroPace. Millions of people living with drug-resistant focal epilepsy face challenges that often go unseen — just like Dr. Al-Hashimi's condition throughout the season. We're proud that the technology we've dedicated ourselves to building is reaching audiences far beyond the hospital. Moments like this matter. They spark conversations, reduce stigma, and remind us why this work is so important. Thank you to the writers and medical consultants of The Pitt for getting this right. https://lnkd.in/gyWKVDyw #NeuroPace #RNSTherapy #Epilepsy #Neuromodulation #ThePitt #PatientAwareness RNS System Safety Info: www.neuropace.com/safety